Shefali Agarwal - 26 Jan 2022 Form 4 Insider Report for Epizyme, Inc. (EPZM)

Role
Executive Vice President, Chief Medical and Development Officer
Signature
/s/ John Weidenbruch, attorney-in-fact
Issuer symbol
EPZM
Transactions as of
26 Jan 2022
Transactions value $
-$5,902
Form type
4
Filing time
28 Jan 2022, 15:15:10 UTC
Previous filing
07 Dec 2021
Next filing
04 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock, par value $0.0001 Sale -$5,902 -2,922 -1.8% $2.02 160,082 26 Jan 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted under the Issuer's 2013 Stock Incentive Plan on January 24, 2019. The automatic sale of the reporting person's shares of Common Stock is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the reporting person.

Remarks:

Executive Vice President, Chief Medical and Development Officer